Literature DB >> 17690596

The attitude of patients towards antipsychotic depot treatment.

Stephan Heres1, Florian Simon Schmitz, Stefan Leucht, Frank-Gerald Pajonk.   

Abstract

In spite of their well known advantages, depot antipsychotics are seldom prescribed in the treatment of schizophrenia. A frequently stated reason is the patient's objection to depot treatment. We questioned 300 patients in nine psychiatric hospitals shortly before their discharge about their preferences in the mode of administration of antipsychotic treatment, taking earlier depot experience into account. 145 patients were naive to depot treatment, 95 had experienced a depot earlier and 60 were currently on a depot medication. Acceptance of depot treatment in relapse prevention was 73% in patients currently being treated with a depot and 45% in depot-experienced patients, compared with 23% in depot-naive participants. Participants, depending on their experience with the formulation, acknowledged suggested potential advantages of depot treatment. Preference of depots as favorable antipsychotic treatment depends on the patient's experience with the formulation. A considerable number of patients would accept a depot drug as a long-term treatment option. The gap between patients' acceptance and the low prescription rates can be narrowed by offering antipsychotic depots to more patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17690596     DOI: 10.1097/YIC.0b013e3280c28424

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  27 in total

Review 1.  The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.

Authors:  Sofia Brissos; Miguel Ruiz Veguilla; David Taylor; Vicent Balanzá-Martinez
Journal:  Ther Adv Psychopharmacol       Date:  2014-10

2.  A test of concordance between patient and psychiatrist valuations of multiple treatment goals for schizophrenia.

Authors:  John F P Bridges; Lara Slawik; Annette Schmeding; Jens Reimer; Dieter Naber; Olaf Kuhnigk
Journal:  Health Expect       Date:  2011-06-14       Impact factor: 3.377

3.  Baseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherence.

Authors:  Katarina Kelin; Alan Jm Brnabic; Richard Newton; Raúl I Escamilla; Liang-Jen Chuo; Malina Simu; Wenyu Ye; William Montgomery; Jamie Karagianis; Haya Ascher-Svanum
Journal:  Patient Prefer Adherence       Date:  2010-09-07       Impact factor: 2.711

Review 4.  Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective.

Authors:  Anna-Sophia Rauch; W Wolfgang Fleischhacker
Journal:  CNS Drugs       Date:  2013-08       Impact factor: 5.749

5.  Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection.

Authors:  Heidi J Wehring; Sheryl Thedford; Maju Koola; Deanna L Kelly
Journal:  J Cent Nerv Syst Dis       Date:  2011-06-01

6.  Attitudes towards the administration of long-acting antipsychotics: a survey of physicians and nurses.

Authors:  Paul Geerts; Guadalupe Martinez; Andreas Schreiner
Journal:  BMC Psychiatry       Date:  2013-02-17       Impact factor: 3.630

7.  Patients' preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study.

Authors:  Istvan Bitter; Tamás Treuer; Nesrin Dilbaz; Igor Oyffe; Eda M Ciorabai; Severiano L Gonzalez; Sandra Ruschel; Jolanta Salburg; Yulia Dyachkova
Journal:  World J Biol Psychiatry       Date:  2010-10       Impact factor: 4.132

8.  Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection.

Authors:  Leslie Citrome
Journal:  Patient Prefer Adherence       Date:  2009-11-29       Impact factor: 2.711

Review 9.  Bromperidol decanoate (depot) for schizophrenia.

Authors:  Marianna Purgato; Clive E Adams
Journal:  Cochrane Database Syst Rev       Date:  2012-11-14

Review 10.  Long-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observations.

Authors:  Giuseppe Rossi; Sonia Frediani; Roberta Rossi; Andrea Rossi
Journal:  BMC Psychiatry       Date:  2012-08-21       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.